Publications

Featured Publications

Peer-Reviewed Original Research

1. Spencer EA. Switching from Intravenous to Subcutaneous Infliximab in Children with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Current Gastroenterology Reports 2026. (in press)
2. Spencer EA, Kellar A, Patel PV, et al. Pediatric Intestinal Ultrasound Across North America: A NASPGHAN Survey of Clinical Capacity and Research Readiness. JPGN Reports 2026.
3. Cutrona M, Cices A, Dubinsky MC, Spencer EA. Acne Therapy with Isotretinoin Is Well Tolerated in Patients with Established IBD: A Retrospective, Single Center Study. Crohn’s & Colitis 360 2026. (in press) (Senior author)
4. Spencer EA, Smyth M, Picararo J, et al. Implementing Intestinal Ultrasound in Pediatric Inflammatory Bowel Disease: Practical Framework for Program Development: Perspectives from the Pediatric Committee of the Intestinal Ultrasound Group of the United States and Canada (iUSCAN). J Pediatr Gastroenterol Nutr 2026.
5. Mochida H, Helmus D, Persaud T, Dubinsky MC, Spencer EA. Parent Perceptions of Disease Monitoring in Pediatric IBD: The Influence of Intestinal Ultrasound Exposure. JPGN Reports 2026. (in press). (Senior author)
6. Spencer EA, Buck Q, Collen LV, et al. Real-World Effectiveness and Safety of Risankizumab Induction and Maintenance Therapy in Pediatric Patients with Crohn’s Disease: A Multicenter Retrospective Analysis. J Crohns Colitis 2026;20(9).
7. Spencer EA, Kothari P, Agrawal M, Wong SY. The Impact of Gender, Rank, and Race on Industry Payments in Pediatric and Adult Gastroenterology. Dig Dis Sci 2026. PMID: 42315724.
8. Spencer EA, et al. Upadacitinib Treatment in Pediatric Crohn’s Disease: 52-week Outcomes of an International Multicenter Retrospective Cohort Study from the Pediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. (in press).
9. Hughes PM, Pittman N, Benkov K, Baez V, Festa J, Kennedy JM, Tung S, Dubinsky MC, Spencer EA. Subcutaneous infliximab in pediatric IBD: Sustained remission, predictable pharmacokinetics, and real-world US implementation. J Pediatr Gastroenterol Nutr 2026. PMID: 42485547. (Senior author)
10. Yerushalmy-Feler A, Cohen S, Spencer EA, et al. Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-Week Multicenter Study From the Porto Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. Clin Gastroenterol Hepatol 2026. PMID: 41713826.
11. Anderson SR, Osman A, Zamani M, Alayo Q, Yarur AJ, Thomas D, Bergstein S, Spencer EA, Sands BE, Rahier JF, Colombel JF, Deepak P. Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2026;32:39-52. PMID: 40845197.
12. Lee SH, Lopes EW, Khalili H, Croitoru K, Colombel JF, Peter I; 2025 PROMISE Workshop participants. Prediction and Prevention of Inflammatory Bowel Disease: A Call to Action. Gastroenterology 2026;170:233-239. PMID: 41410638.
13. Spencer EA, Smyth M, Cices A, Mercurio A, Helmus D, Ungaro RC, Dubinsky MC. Prevalence, age distribution, and impact on management of acne in patients on upadacitinib for inflammatory bowel disease: insights from a single-center survey. Crohns Colitis 360 2026;8:otag036. PMID: 42131777.
14. Yerushalmy-Feler A, Spencer EA, Dolinger MT, Suskind DL, Mitrova K, Hradsky O, Conrad MA, Kelsen JR, Uhlig HH, Tzivinikos C, Ancona S, Wlazlo M, Hackl L, Shouval DS, Bramuzzo M, Urlep D, Olbjorn C, D’Arcangelo G, Pujol-Muncunill G, Yogev D, Kang B, Gasparetto M, Rungø C, Kolho KL, Hojsak I, Norsa L, Rinawi F, Sansotta N, Magen Rimon R, Granot M, Scarallo L, Trindade E, Velasco Rodríguez-Belvís M, Turner D, Cohen S. Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study. J Crohns Colitis 2025;19:jjae182. PMID: 39605286.
15. Weintraub Y, Collen LV, Hussey S, Mitrova K, Machta JS, Kang B, Granot M, D’Arcangelo G, Spencer EA, Kolho KL, Yeh PJ, Sladek M, Scarallo L, Palomino L, Afzal NA, de Laffolie J, Miele E, Bramuzzo M, Olén O, Russell RK, Rohani P, Tzivinikos C, Urlep D, van Rheenen PF, de Ridder L, Yogev D, Schneider AM, Cohen S, Garcia-Romero R, Dipasquale V, Uhlig HH, Shouval DS. Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition. Inflamm Bowel Dis 2025;31:2184-2194. PMID: 39813158.
16. Law CCY, Sheskier R, Viera-Feliciano N, Delgado-Nieves A, Seth S, Hanžel J, Ma C, Colombel JF, Levine AC, Spencer EA; CORE-IBD Collaborators. Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion. Inflamm Bowel Dis 2025;31:3077-3092. PMID: 40587340. (Senior author)
17. Bravo AC, Christensen SG, Julsgaard M, Rodriguez-Lago I, Exposito L, Ginard D, Juillerat P, Sørensen HG, Fiorino G, Buisson A, Stemmer N, Queiroz N, Ribas A, Izquierdo VP, Siegel CA, Croitoiru K, Spencer EA, Peter I, Moss A, Avedano L, Leone S, Colombel JF, Agrawal M, Ungaro R, Fidalgo C, Morão B, Torres J. Patient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease-A Multinational Survey. United European Gastroenterol J 2025;13:1226-1238. PMID: 40827758.
18. Yerushalmy-Feler A, Spencer EA, Bergstein S, Mitrova K, Hradsky O, Bramuzzo M, Wlazlo M, Olbjørn C, Rungoe C, Weil N, Turner D, Cohen S. Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN. Inflamm Bowel Dis 2025;31:3320-3326. PMID: 40834263.
19. Kayal M, Jimenez D, Huang J, Spencer EA. Comparable 12-Week and Superior 24-Week Remission with Risankizumab vs Ustekinumab for Crohn’s-Like Disease of the Pouch. Clin Gastroenterol Hepatol 2025. PMID: 41207520. (Senior author)
20. Dolinger MT, Aronskyy I, Spencer EA, Pittman N, Dubinsky MC. Early intestinal ultrasound response to biologic and small molecule therapy is accurate to predict treat-to-target endoscopic outcomes in children with ulcerative colitis: results from the prospective super sonic-UC study. J Crohns Colitis 2025;19. PMID: 40312920.
21. Smyth MJ, Dolinger MT, Kellar A, Spencer EA, Dubinsky MC. Sonographic Transmural Induction Outcomes Across Advanced Therapies in Crohn’s Disease. Dig Dis Sci 2025;70:3912-3921. PMID: 40618289.
22. Aronskyy I, deBruyn JC, Chugh R, et al; on behalf of the Intestinal Ultrasound Group of the United States and Canada (iUSCAN) Education Committee. Development of an Entrustable Professional Activity for Intestinal Ultrasound in North America. Am J Gastroenterol 2025;120:2735-2741. PMID: 40146035.
23. Yarur AJ, Dervieux T, Ungaro R, Spencer EA, Bruss A, Nunez L, Berens B, Vermeire S, Wang Z, Panetta JC, Dreesen E, Dubinsky MC. Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease. Pharmaceutics 2025;17:187. PMID: 40006554.
24. Cohen S, Spencer EA, Dolinger MT, Suskind DL, Mitrova K, Hradsky O, Conrad MA, Kelsen JR, Uhlig HH, Tzivinikos C, Henderson P, Wlazlo M, Hackl L, Shouval DS, Bramuzzo M, Urlep D, Olbjørn C, D’Arcangelo G, Pujol-Muncunill G, Yogev D, Kang B, Gasparetto M, Rungoe C, Kolho KL, Hojsak I, Norsa L, Rinawi F, Sansotta N, Rimon RM, Granot M, Scarallo L, Trindade E, Rodríguez-Belvís MV, Turner D, Yerushalmy-Feler A. Upadacitinib for Induction of Remission in Paediatric Crohn’s Disease: An International Multicentre Retrospective Study. Aliment Pharmacol Ther 2025. PMID: 39921898.
25. Vermeire S, Dubinsky MC, Rabizadeh S, Panetta JC, Spencer EA, Dreesen E, D’Haens G, Dervieux T, Laharie D. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease. Clin Res Hepatol Gastroenterol 2024;48:102374. PMID: 38750934.
26. Spencer EA, Dubinsky MC, Kamm MA, et al. Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α. Front Immunol 2024;15:1342477. PMID: 38476237.
27. Kellar A, Dolinger MT, Spencer EA, et al. Real-World Outcomes of Dual Advanced Therapy in Children and Young Adults with Inflammatory Bowel Disease. Dig Dis Sci 2024;69:1826-1833. PMID: 38521850.
28. Kayal M, Spencer EA, Smyth M, et al. Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch. Inflamm Bowel Dis 2024. PMID: 39038228.
29. Kayal M, Gottlieb Z, Glamour B, Ibing S, Spencer EA, Dubinsky MC. Acute Pouchitis is Common in Pregnant and Postpartum Women. Clin Transl Gastroenterol 2024;15:e00732. PMID: 38976322.
30. Jacobs JP, Spencer EA, Helmus DS, et al. Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families. Gut 2024. PMID: 39122361.
31. Dolinger MT, Aronskyy I, Kellar A, Spencer EA, Pittman N, Dubinsky MC. Early Intestinal Ultrasound Response to Biologic Therapy Predicts Endoscopic Remission in Children with Ileal Crohn’s Disease: Results from the Prospective Super Sonic Study. J Crohns Colitis 2024;18:1002-1011. PMID: 38141229.
32. Dolinger MT, Aronskyy I, Kellar A, Gao M, Spencer EA, et al. Determining the Accuracy of Intestinal Ultrasound Scores as a Prescreening Tool in Crohn’s Disease Clinical Trials. Am J Gastroenterol 2024;119:930-936. PMID: 38131626.
33. Spencer EA, Dolinger MT, Dubinsky MC. A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2023;68:1121-1124. PMID: 36064828.
34. Spencer EA, Bergstein S, Dolinger M, et al. Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflamm Bowel Dis 2023. PMID: 38134405.
35. Kayal M, Posner H, Spencer EA, et al. Net Remission Rates with Biologic and Small Molecule Treatment in Ulcerative Colitis: A Reappraisal of the Clinical Trial Data. Clin Gastroenterol Hepatol 2023;21:3433-3436.e1. PMID: 36640802.
36. Dubinsky MC, Rabizadeh S, Panetta JC, Spencer EA, et al. The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab. Pharmaceutics 2023;15. PMID: 37896168.
37. Spencer EA, Stachelski J, Dervieux T, et al. Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1*05 Carriage Is Associated With Antidrug Antibody Formation in Patients With Inflammatory Bowel Disease. Gastroenterology 2022;162:1746-1748.e3. PMID: 35026235.
38. Dolinger MT, Rolfes P, Spencer EA, et al. Outcomes of Children with Inflammatory Bowel Disease who Develop Anti-tumour Necrosis Factor-induced Skin Reactions. J Crohns Colitis 2022;16:1420-1427. PMID: 35390140.
39. Spencer EA, Klang E, Dolinger M, et al. Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients. Inflamm Bowel Dis 2021;27:1862-1864. PMID: 34427638.
40. Spencer EA, Jarchin L, Rolfes P, et al. Outcomes of Primary Ileocolic Resection for Pediatric Crohn Disease in the Biologic Era. J Pediatr Gastroenterol Nutr 2021;73:710-716. PMID: 34292216.
41. Dolinger MT, Spencer EA, Lai J, et al. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1210-1214. PMID: 33125058.
42. Spencer EA, Kinnucan J, Wang J, et al. Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers. Crohns Colitis 360 2020;2:otaa022. PMID: 36798650.
43. Spencer EA, Helmus D, Telesco S, et al. Inflammatory Bowel Disease Clusters Within Affected Sibships in Ashkenazi Jewish Multiplex Families. Gastroenterology 2020;159:381-382. PMID: 32199878.
44. Spencer EA, Norris E, Williams C, et al. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD. Inflamm Bowel Dis 2019;25:142-149. PMID: 29920603.
45. Jarchin L, Spencer EA, Khaitov S, et al. De Novo Crohn’s Disease of the Pouch in Children Undergoing Ileal Pouch-Anal Anastomosis for Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2019;69:455-460. PMID: 31136563.
46. Cho S, Spencer EA, Hirten R, et al. Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;68:343-347. PMID: 30320666.
47. Spencer EA, Davis SM, Mack DR, et al. Serologic Reactivity Reflects Clinical Expression of Ulcerative Colitis in Children. Inflamm Bowel Dis 2018;24:1335-1343. PMID: 29718391.

Reviews and Other Peer-Reviewed Publications

1. Spencer EA. Long-term VEDOKIDS results: implications for practice and research. Lancet Gastroenterol Hepatol 2025;10:189-190. PMID: 39788135.
2. Spencer EA, Abbasi S, Kayal M. Barriers to optimizing inflammatory bowel disease care in the United States. Therap Adv Gastroenterol 2023;16:17562848231169652. PMID: 37163167.
3. Spencer EA. Choosing the Right Therapy at the Right Time for Pediatric Inflammatory Bowel Disease: Does Sequence Matter. Gastroenterol Clin North Am 2023;52:517-534. PMID: 37543397.
4. Spencer EA, Dubinsky MC. Reply. Gastroenterology 2022;163:1124-1125. PMID: 35809614.
5. Spencer EA, Agrawal M, Jess T. Prognostication in inflammatory bowel disease. Front Med (Lausanne) 2022;9:1025375. PMID: 36275829.
6. Spencer EA, Dubinsky MC. Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am 2021;68:1171-1190. PMID: 34736583.
7. Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. PMID: 33940007. (Co-first author)
8. Ouahed J, Spencer EA, Kotlarz D, et al. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm Bowel Dis 2020;26:820-842. PMID: 31833544. (Co-first author)
9. Spencer EA, Dubinsky MC. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: History and Future Directions. Pediatr Clin North Am 2017;64:1309-1326. PMID: 29173787.

Book Chapters

1. Spencer EA, Dubinsky MC (2019). Personalized Medicine – Dream or Reality? In: Sheng Ding, N., De Cruz, P. (eds) Biomarkers in Inflammatory Bowel Diseases. Springer, Cham.

A complete and current list is available on ORCID.